Impact of bronchoalveolar lavage on the management of immunocompromised hosts
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: Respiratory infections are an important cause of morbidity and mortality in immunocompromised individuals. Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is an important tool to detect infectious agents in immunocompromised patients with low respiratory tract infections (LRTI).
RESEARCH QUESTION: BAL changes the management of immunocompromised patients with suspected LRTI.
STUDY DESIGN AND METHODS: Immunocompromised patients with a suspicion of LRTI underwent diagnostic BAL. The primary composite outcome consisted of pre-defined modifications in the management of the immunocompromised patients following BAL. We quantified the impact of bronchoscopy up to 30 days after the procedure.
RESULTS: A total of 2666 visits from 1301 patients were included in the study and immunosuppression was classified as haematological (n = 1040; 544 patients), solid organ transplantation (n = 666; 107 patients) and other causes (n = 960; 650 patients). BAL led to a change in management in 52.36% (n = 1396) of all cases. This percentage, as well as the 30-day mortality differed significantly amongst the three groups. Age, C-reactive protein and aetiology of infection determined significantly the risk of 30-day mortality in all patients. In 1.89% (n = 50) of all cases, a combination of 2 respiratory viral agents was identified and 24.23% (n = 646) were diagnosed with a single respiratory viral agent.
INTERPRETATION: BAL leads to changes in management in the majority of immunosuppressed patients. There is a high prevalence of multimicrobial infections and respiratory viral infections in immunocompromised patients with respiratory symptoms. Individual virus infection is associated with diverse risk of a negative outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
European journal of internal medicine - 120(2024) vom: 28. Feb., Seite 52-61 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jahn, Kathleen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bronchoalveolar lavage |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejim.2023.09.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362197660 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362197660 | ||
| 003 | DE-627 | ||
| 005 | 20240206231919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejim.2023.09.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM362197660 | ||
| 035 | |a (NLM)37722932 | ||
| 035 | |a (PII)S0953-6205(23)00327-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jahn, Kathleen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of bronchoalveolar lavage on the management of immunocompromised hosts |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: Respiratory infections are an important cause of morbidity and mortality in immunocompromised individuals. Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is an important tool to detect infectious agents in immunocompromised patients with low respiratory tract infections (LRTI) | ||
| 520 | |a RESEARCH QUESTION: BAL changes the management of immunocompromised patients with suspected LRTI | ||
| 520 | |a STUDY DESIGN AND METHODS: Immunocompromised patients with a suspicion of LRTI underwent diagnostic BAL. The primary composite outcome consisted of pre-defined modifications in the management of the immunocompromised patients following BAL. We quantified the impact of bronchoscopy up to 30 days after the procedure | ||
| 520 | |a RESULTS: A total of 2666 visits from 1301 patients were included in the study and immunosuppression was classified as haematological (n = 1040; 544 patients), solid organ transplantation (n = 666; 107 patients) and other causes (n = 960; 650 patients). BAL led to a change in management in 52.36% (n = 1396) of all cases. This percentage, as well as the 30-day mortality differed significantly amongst the three groups. Age, C-reactive protein and aetiology of infection determined significantly the risk of 30-day mortality in all patients. In 1.89% (n = 50) of all cases, a combination of 2 respiratory viral agents was identified and 24.23% (n = 646) were diagnosed with a single respiratory viral agent | ||
| 520 | |a INTERPRETATION: BAL leads to changes in management in the majority of immunosuppressed patients. There is a high prevalence of multimicrobial infections and respiratory viral infections in immunocompromised patients with respiratory symptoms. Individual virus infection is associated with diverse risk of a negative outcome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bronchoalveolar lavage | |
| 650 | 4 | |a Fiberoptic bronchoscopy | |
| 650 | 4 | |a Immunocompromised host | |
| 650 | 4 | |a Immunocompromised lung disease | |
| 650 | 4 | |a Infections in immunocompromised patients | |
| 700 | 1 | |a Karakioulaki, Meropi |e verfasserin |4 aut | |
| 700 | 1 | |a Schumann, Desiree M |e verfasserin |4 aut | |
| 700 | 1 | |a Hirsch, Hans H |e verfasserin |4 aut | |
| 700 | 1 | |a Leuzinger, Karoline |e verfasserin |4 aut | |
| 700 | 1 | |a Grize, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Aliberti, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Sotgiu, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Tamm, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Stolz, Daiana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of internal medicine |d 1997 |g 120(2024) vom: 28. Feb., Seite 52-61 |w (DE-627)NLM089689097 |x 1879-0828 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2024 |g day:28 |g month:02 |g pages:52-61 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejim.2023.09.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2024 |b 28 |c 02 |h 52-61 | ||